Last reviewed · How we verify
Intravenous neostigmine and atropine
Intravenous neostigmine and atropine is a Small molecule drug developed by Mansoura University. It is currently in Phase 1 development.
At a glance
| Generic name | Intravenous neostigmine and atropine |
|---|---|
| Sponsor | Mansoura University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Procedural pain
- Nausea
- Vomiting
- C-reactive protein increased
- Constipation
- Procedural vomiting
- Abdominal Pain
- Musculoskeletal pain
- Procedural nausea
- Bradycardia
- Pyrexia
- Postoperative wound infection
Key clinical trials
- Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169) (PHASE4)
- Effects Of Anaesthesia on Intraocular Pressure in Robotic Prostate Surgery (NA)
- Clinical Efficacy of Prophylactic Intravenous Neostigmine and Atropine in Preventing Post-Dural Puncture Headache Among Parturient Undergoing Spinal Anesthesia for Cesarean Section: A Double-blind Randomized Placebo-controlled Trial (PHASE4)
- Open and Laparoscopic Total Extraperitoneal Repair Under Spinal Anesthesia Versus General Anesthesia (NA)
- Comparative Study of Ketamine Added to Bupivacaine in PECS Block Versus Topical Wound Instillation on Post Operative Analgesia in Modified Radical Mastectomy Surgery (EARLY_PHASE1)
- Total Knee Replacement TIVA With Robotic Arm Assisted (PHASE4)
- Pharmacokinetic-pharmacodynamic Analysis of Sugammadex in Children (PHASE2)
- Opioid Free Anesthesia in Thoracic Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous neostigmine and atropine CI brief — competitive landscape report
- Intravenous neostigmine and atropine updates RSS · CI watch RSS
- Mansoura University portfolio CI
Frequently asked questions about Intravenous neostigmine and atropine
What is Intravenous neostigmine and atropine?
Intravenous neostigmine and atropine is a Small molecule drug developed by Mansoura University.
Who makes Intravenous neostigmine and atropine?
Intravenous neostigmine and atropine is developed by Mansoura University (see full Mansoura University pipeline at /company/mansoura-university).
What development phase is Intravenous neostigmine and atropine in?
Intravenous neostigmine and atropine is in Phase 1.
What are the side effects of Intravenous neostigmine and atropine?
Common side effects of Intravenous neostigmine and atropine include Procedural pain, Nausea, Vomiting, C-reactive protein increased, Constipation, Procedural vomiting.
Related
- Manufacturer: Mansoura University — full pipeline